A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Sponsor
Bristol-Myers Squibb
Study ID
NCT04196452
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Ipilimumab — DRUG
    Specified dose on specified days

Study Details

This is an observational, national, retrospective study consisting of pediatric patients with advanced (spread or unremoveable) melanoma identified in the DMTR in the Netherlands

Key Dates

Start date
Aug 12, 2019
Status verified
Nov 2025
Primary completion
Feb 20, 2034
Completion
Jul 24, 2034

Study Design

Enrollment
10 participants (estimated)

Arms

  • Arm: Arm A: participants 12 to under 18
  • Arm: Arm B: participants under 12

Primary Outcome Measure

Frequency of Adverse Events (AEs) Grades 3-4 [ Time Frame: up to 10 years ]

Related Studies